Palbociclib vs Ribociclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
Palbociclib · Ibrance
Marketed by Pfizer
NCT01740427 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.
Next expected readout: November 2026 · NCT02605486 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) (met)
Result source: NCT02297438
Ribociclib
Marketed by Novartis
NCT02422615 · Phase 3 · completed
The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.
Next expected readout: November 2026 · NCT02608216 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) (met)
Result source: NCT02422615
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Palbociclib | Ribociclib |
|---|---|---|
| PFS, median | 24.8 vs 14.5+10.3 vs placeboNCT0174042720 other results
| 20.5 vs 12.8+7.7 vs placeboNCT024226159 other results
|
| OS, median | 53.9 vs 51.2+2.7 vs placeboNCT0174042714 other results
| 63.9 vs 51.4+12.5 vs placeboNCT019580211 other result
|
| ORR | 46.4% vs 38.3%+8.1 vs placeboNCT0174042715 other results
| 32.4% vs 21.5%+10.9 vs placeboNCT024226156 other results
|
| Clinical benefit rate | 85.8% vs 71.2%+14.6 vs placeboNCT0174042710 other results
| 70.2% vs 62.8%+7.4 vs placeboNCT024226154 other results
|
PFS, median
- Palbociclib
- 24.8 vs 14.5+10.3 vs placeboNCT01740427
20 other results
- 21.5 vs 13.9 NCT02297438
- 9.2 vs 3.8 NCT01942135
- 7.3 vs 10 NCT02028507
- 7.5 vs 10 NCT02028507
- 21.6 vs 16.4 NCT02297438
- 8 vs 10.6 NCT02028507
- 20.2 vs 10.2 NCT00721409
- 26.1 vs 10.2 NCT00721409
- 18.1 vs 10.2 NCT00721409
- 11.3 NCT02630693
- 9.3 NCT02630693
- 9.1 NCT02668666
- 16.9 NCT03530696
- 8.3 NCT03530696
- 4.1 NCT02913430
- 9.4 NCT02384239
- 6.5 NCT02384239
- 29.4 NCT03633331
- 30.4 NCT03691493
- 18.6 NCT02499146
- Ribociclib
- 20.5 vs 12.8+7.7 vs placeboNCT02422615
9 other results
- 23.8 vs 13 NCT02278120
- 21.8 NCT03096847
- 8.8 NCT03096847
- 16.5 NCT03096847
- 27.6 vs 14.7 NCT03671330
- 5.3 vs 2.8 NCT02632045
- 21.8 vs 12.8 NCT03839823
- 25.1 NCT03822468
- 26.9 NCT03822468
OS, median
- Palbociclib
- 53.9 vs 51.2+2.7 vs placeboNCT01740427
14 other results
- 53.8 vs 49.8 NCT01740427
- 51.7 vs 51.5 NCT02297438
- 50.3 vs 49.7 NCT02297438
- 34.9 vs 28 NCT01942135
- 33.7 vs 32 NCT02028507
- 37.5 vs 34.5 NCT00721409
- 37.5 vs 34.5 NCT00721409
- 35.1 vs 34.5 NCT00721409
- 21.4 NCT02630693
- 20.7 NCT02630693
- 35.6 NCT03633331
- 35.1 NCT03530696
- 37.9 NCT03691493
- 18.8 NCT02913430
- Ribociclib
- 63.9 vs 51.4+12.5 vs placeboNCT01958021
1 other result
- 69.2 vs 55.5 NCT03671330
ORR
- Palbociclib
- 46.4% vs 38.3%+8.1 vs placeboNCT01740427
15 other results
- 37.3% vs 31.6% NCT02297438
- 43.4% vs 38% NCT02297438
- 40.2% vs 33.9% NCT02297438
- 52.3% vs 43.5% NCT02297438
- 21% vs 8.6% NCT01942135
- 42.9% vs 33.3% NCT00721409
- 44.1% vs 33.3% NCT00721409
- 42% vs 33.3% NCT00721409
- 55.4% vs 39.4% NCT00721409
- 55.6% vs 39.4% NCT00721409
- 55.3% vs 39.4% NCT00721409
- 47.6% NCT01684215
- 30% NCT02668666
- 33.3% NCT00721409
- 19.2% NCT02499146
- Ribociclib
- 32.4% vs 21.5%+10.9 vs placeboNCT02422615
6 other results
- 40.9% vs 29.7% NCT02278120
- 40.7% vs 27.5% NCT01958021
- 29.3% NCT02941926
- 45.3% NCT03822468
- 41.5% NCT03822468
- 66.1% vs 61.8% NCT03839823
Clinical benefit rate
- Palbociclib
- 85.8% vs 71.2%+14.6 vs placeboNCT01740427
10 other results
- 79.3% vs 80.1% NCT02297438
- 77.9% vs 79.6% NCT02297438
- 76.9% vs 73.1% NCT02297438
- 78.1% vs 71.8% NCT02297438
- 66.3% vs 39.7% NCT01942135
- 81% vs 58% NCT00721409
- 76.5% vs 58% NCT00721409
- 84% vs 58% NCT00721409
- 64% NCT02668666
- 83.3% NCT00721409
- Ribociclib
- 70.2% vs 62.8%+7.4 vs placeboNCT02422615
4 other results
- 79.1% vs 69.7% NCT02278120
- 79.6% vs 72.8% NCT01958021
- 70.7% NCT02941926
- 81.3% vs 74.5% NCT03839823
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety
Coverage. Palbociclib: 16 of 16 rows · Ribociclib: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Palbociclib Rows use multiple source trials | Ribociclib Rows use multiple source trials |
|---|---|---|
| Clinical Benefit event count · % of participants | 76.2% (n=206) vs 82.4% (n=187) Capecitabine*a,b,c NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted | 43.3% (n=60) vs 25.4% (n=59) placebo @ 24wk*a,b,c NCT02632045 · Phase 2 · registry result, not featured evidence · combination · converted to % from 26 Participants as posted |
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 64% (n=47)d,b,e,c NCT02668666 · Phase 2 · registry result, not featured evidence 1 other source trial83.3% (n=12) NCT00721409 · Phase 2 · registry result, not featured evidence · combination | 70.7% (n=3246)d,b,e,c NCT02941926 · Phase 3 · combination |
| Clinical Benefit event count · % of participants No placebo or comparator arm | 83.3% (n=54)*b,e,c NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted 4 other source trials40% (n=5) @ 26wk* NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted 60% (n=5)* NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted 50% (n=2) @ 26wk* NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 100% (n=2)* NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted | 70.7% (n=188)*600 mgf,b,e,c NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 133 Participants as posted show 1 more dose75.5% (n=188)*400 mg NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 142 Participants as posted |
| Duration of Response time to event · months | 20.1 vs 16.7 placebo monthsg,c NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 7 other source trials10.4 vs 9 Fulvestrant months NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 22.4 vs 19.4 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 30.3 vs 24.9 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9.7 vs 11.2 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 20.9 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20.2 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20.3 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination | NA vs NA placebo monthsg,c NCT02422615 · Phase 3 · combination 3 other source trials21.3 vs 17.5 placebo months NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 45.2 vs 17.6 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence 37 vs 17.6 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence |
| Duration of Response time to event · months No placebo or comparator arm | 5.55 months*125mgf,b,e,c NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 169 days as posted show 1 more dose4.14 months*100mg NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 126 days as posted | 28.8 months600 mgf,b,e,c NCT03822468 · Phase 2 · registry result, not featured evidence show 1 more dose26.5 months400 mg NCT03822468 · Phase 2 · registry result, not featured evidence |
| FACT-B absolute change · score No placebo or comparator arm End of Treatment | -9.17 score125 mg + 2.5 mgd,h,c End of Treatment NCT01684215 · Phase 2 · registry result, not featured evidence · combination | |
| ORR event count · % of participants | 22.8% (n=206) vs 29.4% (n=187) Capecitabine*a,b,c NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted | 20% (n=35) vs 11.4% (n=35) placebo*a,b,c NCT02632045 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 participants as posted |
| ORR responder rate · % of participants No placebo or comparator arm | 30% (n=47)d,b,e,c NCT02668666 · Phase 2 · registry result, not featured evidence 3 other source trials47.6% (n=42)125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 33.3% (n=12) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 19.2% (n=26) NCT02499146 · Phase 1 · registry result, not featured evidence · combination | 29.3% (n=3246)d,b,e,c NCT02941926 · Phase 3 · combination 2 other source trials41.5% (n=188)400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 45.3% (n=188)600 mg NCT03822468 · Phase 2 · registry result, not featured evidence |
| ORR event count · % of participants No placebo or comparator arm | 33.3% (n=54)*b,c NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted 8 other source trials0% (n=3) @ 24wk*100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=3) @ 24wk*150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 6.7% (n=15) @ 24wk*150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted 10% (n=10) @ 24wk*300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted 0% (n=16) @ 24wk*50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=6) @ 24wk*75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=3) @ 24wk*75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 4% (n=75) @ 24wk*50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 3 Participants as posted | 50% (n=2)*b,c NCT03477396 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted |
| Overall Survival time to event · months No placebo or comparator arm | 35.61 months*d,b,c NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1084 days as posted 8 other source trials20.73 months100mg NCT02630693 · Phase 2 · registry result, not featured evidence 21.39 months125mg NCT02630693 · Phase 2 · registry result, not featured evidence NA months NCT03530696 · Phase 2 · registry result, not featured evidence 35.1 months NCT03530696 · Phase 2 · registry result, not featured evidence · combination 37.9 months NCT03691493 · Phase 2 · registry result, not featured evidence · combination NA months125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination NA months NCT02913430 · Phase 1 · registry result, not featured evidence · combination 18.7541 months NCT02913430 · Phase 1 · registry result, not featured evidence · combination | NA monthsf,d,b,c NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more dosesNA months NCT03096847 · Phase 3 · registry result, not featured evidence · combination NA months NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| Overall Survival responder rate · % of participants No placebo or comparator arm | 90% (n=10) @ 48wk300 mg QDf,i,b,j NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy show 7 more doses100% (n=3) @ 48wk150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100% (n=15) @ 48wk150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100% (n=3) @ 48wk100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 83.3% (n=6) @ 48wk75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100% (n=3) @ 48wk75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100% (n=16) @ 48wk50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 84.2% (n=75) @ 48wk50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy | 93.3% (n=307) @ 48wkf,i,b,j NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more doses87.5% (n=26) @ 48wk NCT03096847 · Phase 3 · registry result, not featured evidence · combination 86.1% (n=154) @ 48wk NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 29.4 months*d,b,c NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted 11 other source trials9.33 months100mg NCT02630693 · Phase 2 · registry result, not featured evidence 11.3 months125mg NCT02630693 · Phase 2 · registry result, not featured evidence 9.13 months NCT02668666 · Phase 2 · registry result, not featured evidence 8.3 months NCT03530696 · Phase 2 · registry result, not featured evidence 16.9 months NCT03530696 · Phase 2 · registry result, not featured evidence · combination 30.4 months NCT03691493 · Phase 2 · registry result, not featured evidence · combination 6.53 months100mg NCT02384239 · Phase 2 · registry result, not featured evidence 9.4 months125mg NCT02384239 · Phase 2 · registry result, not featured evidence 18.6 months NCT02499146 · Phase 1 · registry result, not featured evidence · combination 4.131147 months NCT02913430 · Phase 1 · registry result, not featured evidence · combination NA months NCT02913430 · Phase 1 · registry result, not featured evidence · combination | 21.8 monthsf,d,b,c NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more doses16.5 months NCT03096847 · Phase 3 · registry result, not featured evidence · combination 8.8 months NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | n/a: no completion milestonek NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 55 more resultsn/a: no completion milestone NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestone NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 69.1%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 34%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02600923 · Phase 3 · registry result, not featured evidence · combination 0% NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 1.1% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 87.5% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 1.1%125mg NCT02630693 · Phase 2 · registry result, not featured evidence 0%100mg NCT02630693 · Phase 2 · registry result, not featured evidence 0% NCT02668666 · Phase 2 · registry result, not featured evidence 1.4% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 1.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02536742 · Phase 2 · registry result, not featured evidence 12.5%Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence 2.6%T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination 2.8% NCT03691493 · Phase 2 · registry result, not featured evidence · combination 0%125mg NCT02384239 · Phase 2 · registry result, not featured evidence 0%100mg NCT02384239 · Phase 2 · registry result, not featured evidence n/a: no completion milestone125 mg NCT01684215 · Phase 2 · registry result, not featured evidence —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT01684215 · Phase 2 · registry result, not featured evidence —Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 100%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 97.6%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone NCT02499146 · Phase 1 · registry result, not featured evidence · combination 0%Fulvestrant + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination 0%Tamoxifen + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination —8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination | n/a: no completion milestoneRibociclib + Fulvestrantl NCT02422615 · Phase 3 · combination show 27 more results—Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination n/a: no completion milestoneRibociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestoneRibociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 59.9% NCT02941926 · Phase 3 · combination 68.7%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 76.9%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 87.9%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestonePK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePostmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePremenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestone600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence n/a: no completion milestone400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0% NCT03477396 · Phase 2 · registry result, not featured evidence · combination 68.8%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 3.2% NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 7.2%k NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 55 more results8.9% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 — NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3.9%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 2%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 5.2%Cohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 2%Cohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination — NCT03633331 · Phase 2 · registry result, not featured evidence · combination — NCT04224272 · Phase 2 · registry result, not featured evidence · combination —125mg NCT02630693 · Phase 2 · registry result, not featured evidence —100mg NCT02630693 · Phase 2 · registry result, not featured evidence — NCT02668666 · Phase 2 · registry result, not featured evidence — NCT03644186 · Phase 2 · registry result, not featured evidence · combination — NCT03007979 · Phase 2 · registry result, not featured evidence · combination — NCT02536742 · Phase 2 · registry result, not featured evidence —Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence —T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination — NCT03691493 · Phase 2 · registry result, not featured evidence · combination —125mg NCT02384239 · Phase 2 · registry result, not featured evidence —100mg NCT02384239 · Phase 2 · registry result, not featured evidence 0%125 mg NCT01684215 · Phase 2 · registry result, not featured evidence —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 16.7%100 mg NCT01684215 · Phase 2 · registry result, not featured evidence —Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 0%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 15.5%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 11.5% NCT02499146 · Phase 1 · registry result, not featured evidence · combination —Fulvestrant + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination —Tamoxifen + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination —8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 50%8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 33.3%6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 0%5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination | 10.5%Ribociclib + Fulvestrantl NCT02422615 · Phase 3 · combination show 27 more results—Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination 4.8%Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 11.4%Ribociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 15.5% NCT02941926 · Phase 3 · combination 22.6%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 23.1%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 17.8%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 11.8%PK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence 6.5%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 1.3%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 12.8%600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence 11.2%400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence — NCT03477396 · Phase 2 · registry result, not featured evidence · combination 7.1%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence — NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 28.2%k NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 55 more results22.6% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 20.2% NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 29.6%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 18%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 22.7%Cohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 14.1%Cohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 24.6% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 38% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 15.7% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 13.5%125mg NCT02630693 · Phase 2 · registry result, not featured evidence 10%100mg NCT02630693 · Phase 2 · registry result, not featured evidence 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 54.2% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 73% NCT02536742 · Phase 2 · registry result, not featured evidence 21.4%Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence 21.1%T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination — NCT03691493 · Phase 2 · registry result, not featured evidence · combination 5.9%125mg NCT02384239 · Phase 2 · registry result, not featured evidence 13.9%100mg NCT02384239 · Phase 2 · registry result, not featured evidence 0%125 mg NCT01684215 · Phase 2 · registry result, not featured evidence 9.5%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 33.3%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 0%100 mg NCT01684215 · Phase 2 · registry result, not featured evidence 30.3%Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 24%Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 16.7%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 26.5%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20%300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 33.3%150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 0%150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 13.3%150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 16.7%100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 33.3%100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 16.7%75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 11.1%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 0%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 12%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 20%25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 40%25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 100%125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 83.3%100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 87.5%100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 15.4% NCT02499146 · Phase 1 · registry result, not featured evidence · combination 40%Fulvestrant + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination 0%Tamoxifen + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination 25%8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 16.7%6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 33.3%5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination | —Ribociclib + Fulvestrantl NCT02422615 · Phase 3 · combination show 27 more results37.1%Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 24.2%Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 25%Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 32.3%Ribociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 — NCT02941926 · Phase 3 · combination 30.4%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination 27.3%Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 19.2%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 28.7%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination —PK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 29.4%PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence 0%PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 27.3%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 0%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 17.7%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 0%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —600 mg NCT03822468 · Phase 2 · registry result, not featured evidence 19.7%600mg NCT03822468 · Phase 2 · registry result, not featured evidence —400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 20.2%400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0% NCT03477396 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 15.2%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 6.7% NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | k neutropenia 69.4% (placebo 3.6%) arthralgia 42.1% (placebo 40.1%) fatigue 41.2% (placebo 29.3%) NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 49 more resultsneutropenia 67% fatigue 43.8% nausea 36.5% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutrophil count decreased 66.7% (placebo 11.1%) white blood cell count decreased 64.3% (placebo 9.9%) neutropenia 44.6% (placebo 7%) NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 72.4% fatigue 65.1% nausea 37.5% NCT02679755 · Phase 4 · registry result, not featured evidence · combination neutropenia 57% anaemia 22% alopecia 17% NCT02679755 · Phase 4 · registry result, not featured evidence · combination neutrophil count decreased 62.7% fatigue 55.3% hypertension 34% NCT02028507 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 63.1% fatigue 51% hypertension 36.9% NCT02028507 · Phase 3 · registry result, not featured evidence · combination neutropenia 70% leukopenia 34.6% anaemia 33.8% NCT02600923 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 92.4% white blood cell decreased 87% fatigue 84.8% NCT03633331 · Phase 2 · registry result, not featured evidence · combination diarrhoea 92.2% nausea 52.9% stomatitis 41.2% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 125mg fatigue 82% nausea 53.9% back pain 46.1% NCT02630693 · Phase 2 · registry result, not featured evidence 100mg fatigue 85.6% nausea 52.2% insomnia 48.9% NCT02630693 · Phase 2 · registry result, not featured evidence neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence diarrhea 65.3% anemia 48.6% platelet count decreased 38.9% NCT03644186 · Phase 2 · registry result, not featured evidence · combination white blood cell count decreased 96.3% neutrophil count decreased 87% anemia 79.6% NCT03007979 · Phase 2 · registry result, not featured evidence · combination nausea 57.1% aspartate aminotransferase increased 50% fatigue 50% NCT03530696 · Phase 2 · registry result, not featured evidence neutrophil count decreased 84.2% platelet count decreased 76.3% white blood cell count decreased 76.3% NCT03530696 · Phase 2 · registry result, not featured evidence · combination 125mg neutrophil count decreased 26.5% hypertension 0% NCT02384239 · Phase 2 · registry result, not featured evidence 100mg neutrophil count decreased 13.9% hypertension 5.6% NCT02384239 · Phase 2 · registry result, not featured evidence 125 mg white blood cell count decreased 83.3% diarrhoea 66.7% neutrophil count decreased 66.7% NCT01684215 · Phase 2 · registry result, not featured evidence 125 mg + 2.5 mg neutrophil count decreased 81% stomatitis 76.2% white blood cell count decreased 71.4% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 125 mg + 2.5 mg neutrophil count decreased 100% white blood cell count decreased 100% diarrhoea 66.7% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 100 mg neutrophil count decreased 83.3% white blood cell count decreased 66.7% aspartate aminotransferase increased 33.3% NCT01684215 · Phase 2 · registry result, not featured evidence neutropenia 78.8% leukopenia 48.5% fatigue 42.4% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 72% fatigue 40% leukopenia 40% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 91.7% fatigue 83.3% leukopenia 66.7% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 74.7% leukopenia 43.4% fatigue 41% NCT00721409 · Phase 2 · registry result, not featured evidence · combination 300 mg QD nausea 40% fatigue 30% headache 30% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 150 mg QD neutrophil count decreased 100% anaemia 66.7% fatigue 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 150 mg BID abdominal pain 66.7% ggt increased 66.7% nausea 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 150 mg QD nausea 40% headache 26.7% hypertension 26.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100 mg QD white blood cell count decreased 91.7% neutrophil count decreased 58.3% anaemia 41.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 100 mg QD abdominal pain upper 33.3% arthralgia 33.3% back pain 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 75 mg BID arthralgia 33.3% fall 33.3% fatigue 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 75 mg QD hypophosphataemia 66.7% blood alkaline phosphatase increased 33.3% breast pain 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 50 mg BID alt increased 50% anaemia 50% cough 50% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 50 mg QD neutrophil count decreased 77.8% white blood cell count decreased 77.8% anaemia 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 50 mg QD fatigue 25% ggt increased 18.8% arthralgia 12.5% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 50 mg QD ggt increased 14.7% covid-19 10.7% ast increased 9.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 25 mg BID nausea 60% neutrophil count decreased 60% white blood cell count decreased 60% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 25 mg QD neutrophil count decreased 80% white blood cell count decreased 70% anaemia 50% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 125mg mucositis oral 100% neutrophil count decreased 100% platelet count decreased 100% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 100mg mucositis oral 100% neutrophil count decreased 83.3% fatigue 50% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 100mg mucositis oral 96.9% neutrophil count decreased 87.5% fatigue 65.6% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination neutrophil count decreased 61.5% platelet count decreased 57.7% white blood cell count decreased 57.7% NCT02499146 · Phase 1 · registry result, not featured evidence · combination dyspnea 60% neutrophil count decreased 60% skin and subcutaneous tissue disorders - other 60% NCT02913430 · Phase 1 · registry result, not featured evidence · combination blood and lymphatic system disorders - other 50% hypertension 50% neutrophil count decreased 50% NCT02913430 · Phase 1 · registry result, not featured evidence · combination 8 mg diarrhea 75% oral mucositis 75% dry skin 50% NCT03238196 · Phase 1 · registry result, not featured evidence · combination 6 mg fatigue 83.3% oral mucositis 83.3% dry mouth 66.7% NCT03238196 · Phase 1 · registry result, not featured evidence · combination 5 mg anemia 100% constipation 100% dry skin 100% NCT03238196 · Phase 1 · registry result, not featured evidence · combination | l neutropenia 57.8% (placebo 2.5%) nausea 46.8% (placebo 31.1%) diarrhoea 34% (placebo 22.4%) NCT02422615 · Phase 3 · combination show 18 more resultsneutropenia 57.9% (placebo 6.5%) arthralgia 38.8% (placebo 36.2%) neutrophil count decreased 35.5% (placebo 1.5%) NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 nausea 75% (placebo 32.1%) anaemia 50% (placebo 7.3%) diarrhoea 50% (placebo 26.7%) NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 65.3% (placebo 5.5%) nausea 54.8% (placebo 32.1%) fatigue 43.4% (placebo 36.1%) NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 50.8% nausea 40.8% fatigue 38.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 48.1% nausea 42.1% fatigue 40.4% NCT03096847 · Phase 3 · registry result, not featured evidence · combination fatigue 57.7% neutropenia 57.7% hot flush 42.3% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 46.5% nausea 43.3% fatigue 37.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 100% (placebo 23.4%) white blood cell count decreased 100% (placebo 33.8%) anaemia 94.1% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence aspartate aminotransferase increased 12.5% (placebo 40.3%) blood alkaline phosphatase increased 6.3% (placebo 27.3%) blood cholesterol increased 6.3% (placebo 16.9%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 85.7% (placebo 23.4%) white blood cell count decreased 80.5% (placebo 33.8%) anaemia 48.1% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 1.4% (placebo 40.3%) aspartate aminotransferase increased 1.4% (placebo 40.3%) blood bilirubin increased 1.4% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 88.6% (placebo 23.4%) white blood cell count decreased 87.3% (placebo 33.8%) anaemia 55.7% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 2.7% (placebo 23.4%) alanine aminotransferase increased 1.4% (placebo 40.3%) aspartate aminotransferase increased 1.4% (placebo 40.3%) NCT03671330 · Phase 2 · registry result, not featured evidence 600mg neutropenia 66.5% leukopenia 27.7% anaemia 26.1% NCT03822468 · Phase 2 · registry result, not featured evidence 400mg neutropenia 53.2% alanine aminotransferase increased 26.1% aspartate aminotransferase increased 21.8% NCT03822468 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 100% alkaline phosphatase increased 100% aspartate aminotransferase increased 100% NCT03477396 · Phase 2 · registry result, not featured evidence · combination 600 mg neutropenia 65.2% anaemia 35.7% leukopenia 25.9% NCT03839823 · Phase 2 · registry result, not featured evidence neutropenia 71.7% (placebo 15.3%) fatigue 33.3% (placebo 32.2%) aspartate aminotransferase increased 25% (placebo 28.8%) NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cThe assessment timepoint is not available for both results.
- dTrial phases differ: Phase 3 versus Phase 2.
- eTreatment context has not been resolved for both arms.
- fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- gPopulation context differs: eligible sex differs (ALL versus FEMALE).
- hPopulation context differs: registered conditions differ.
- iTrial phases differ: Phase 3 versus Phase 1/2.
- jTreatment context differs: combination versus monotherapy.
- kPopulation comparability has not been reviewed for 53 of these studies.
- lPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Palbociclib
show 1 more result
show 1 more result
show 3 more results
+ 61 further endpoints in the CSV export.
Ribociclib
show 4 more results
+ 34 further endpoints in the CSV export.
Breast Cancer
Shared mechanism: CDK4 and CDK6 · full Breast Cancer pipeline
Palbociclib · Ibrance
Marketed by Pfizer
NCT01740427 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.
Next expected readout: November 2026 · NCT02605486 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) (met)
Result source: NCT02297438
Ribociclib
Marketed by Novartis
NCT02422615 · Phase 3 · completed
The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.
Next expected readout: November 2026 · NCT02608216 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) (met)
Result source: NCT02422615
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Palbociclib: 21 of 21 rows · Ribociclib: 21 of 21 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Palbociclib Rows use multiple source trials | Ribociclib Rows use multiple source trials |
|---|---|---|
| Clinical Benefit responder rate · % of participants | 85.8% (n=444) vs 71.2% (n=222) placeboa,b NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 8 other source trials66.3% (n=347) vs 39.7% (n=174) Fulvestrant NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 79.3% (n=169) vs 80.1% (n=171) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 77.9% (n=145) vs 79.6% (n=142) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 76.9% (n=169) vs 73.1% (n=171) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 78.1% (n=128) vs 71.8% (n=131) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 76.5% (n=34) vs 58% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 84% (n=50) vs 58% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 81% (n=84) vs 58% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination | 70.2% (n=484) vs 62.8% (n=242) placeboa,b NCT02422615 · Phase 3 · combination 3 other source trials79.1% (n=335) vs 69.7% (n=337) placebo NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 79.6% (n=334) vs 72.8% (n=334) placebo NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 81.3% (n=112) vs 74.5% (n=110) Combination Chemotherapy600 mg NCT03839823 · Phase 2 · registry result, not featured evidence |
| Clinical Benefit event count · % of participants | 76.2% (n=206) vs 82.4% (n=187) Capecitabine*c,d,b NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted | 43.3% (n=60) vs 25.4% (n=59) placebo @ 24wk*c,d,b NCT02632045 · Phase 2 · registry result, not featured evidence · combination · converted to % from 26 Participants as posted |
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 64% (n=47)e,d,f,b NCT02668666 · Phase 2 · registry result, not featured evidence 1 other source trial83.3% (n=12) NCT00721409 · Phase 2 · registry result, not featured evidence · combination | 70.7% (n=3246)e,d,f,b NCT02941926 · Phase 3 · combination |
| Clinical Benefit event count · % of participants No placebo or comparator arm | 83.3% (n=54)*d,f,b NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted 10 other source trials0.67% (n=36) @ 24wk100mg NCT02384239 · Phase 2 · registry result, not featured evidence 0.75% (n=32) @ 24wk125mg NCT02384239 · Phase 2 · registry result, not featured evidence 33.3% (n=3) @ 24wk*100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted 33.3% (n=3) @ 24wk*150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted 26.7% (n=15) @ 24wk*150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 4 Participants as posted 50% (n=10) @ 24wk*300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 5 Participants as posted 43.8% (n=16) @ 24wk*50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 7 Participants as posted 16.7% (n=6) @ 24wk*75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted 0% (n=3) @ 24wk*75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 50.7% (n=75) @ 24wk*50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 38 Participants as posted | 70.7% (n=188)*600 mgg,d,f,b NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 133 Participants as posted show 1 more dose75.5% (n=188)*400 mg NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 142 Participants as posted |
| Duration of Response time to event · months | 20.1 vs 16.7 placebo monthsa,b NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 7 other source trials10.4 vs 9 Fulvestrant months NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 22.4 vs 19.4 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 30.3 vs 24.9 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9.7 vs 11.2 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 20.9 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20.2 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20.3 vs 11.1 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination | NA vs NA placebo monthsa,b NCT02422615 · Phase 3 · combination 3 other source trials21.3 vs 17.5 placebo months NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 45.2 vs 17.6 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence 37 vs 17.6 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence |
| Duration of Response time to event · months No placebo or comparator arm | 5.55 months*125mgg,d,f,b NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 169 days as posted show 1 more dose4.14 months*100mg NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 126 days as posted | 28.8 months600 mgg,d,f,b NCT03822468 · Phase 2 · registry result, not featured evidence show 1 more dose26.5 months400 mg NCT03822468 · Phase 2 · registry result, not featured evidence |
| FACT-B absolute change · score No placebo or comparator arm End of Treatment | -9.17 score125 mg + 2.5 mge,h,b End of Treatment NCT01684215 · Phase 2 · registry result, not featured evidence · combination | |
| ORR responder rate · % of participants | 46.4% (n=444) vs 38.3% (n=222) placeboa,b NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 12 other source trials21% (n=347) vs 8.6% (n=174) Fulvestrant NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 37.3% (n=169) vs 31.6% (n=171) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 43.4% (n=145) vs 38% (n=142) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 40.2% (n=169) vs 33.9% (n=171) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 52.3% (n=128) vs 43.5% (n=131) placebo NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 50% (n=112) vs 49.1% (n=108) Anastrozole + Palbociclib @ 12wk NCT04436744 · Phase 2 · registry result, not featured evidence · combination 44.1% (n=34) vs 33.3% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 55.6% (n=27) vs 39.4% (n=66) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 42% (n=50) vs 33.3% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 55.3% (n=21) vs 39.4% (n=66) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 42.9% (n=84) vs 33.3% (n=81) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination 55.4% (n=65) vs 39.4% (n=66) Letrozole NCT00721409 · Phase 2 · registry result, not featured evidence · combination | 32.4% (n=484) vs 21.5% (n=242) placeboa,b NCT02422615 · Phase 3 · combination 3 other source trials40.9% (n=335) vs 29.7% (n=337) placebo NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 40.7% (n=334) vs 27.5% (n=334) placebo NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 66.1% (n=112) vs 61.8% (n=110) Combination Chemotherapy600 mg NCT03839823 · Phase 2 · registry result, not featured evidence |
| ORR event count · % of participants | 22.8% (n=206) vs 29.4% (n=187) Capecitabine*c,d,b NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted | 20% (n=35) vs 11.4% (n=35) placebo*c,d,b NCT02632045 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 participants as posted |
| ORR responder rate · % of participants No placebo or comparator arm | 30% (n=47)e,d,f,b NCT02668666 · Phase 2 · registry result, not featured evidence 2 other source trials47.6% (n=42)125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 33.3% (n=12) NCT00721409 · Phase 2 · registry result, not featured evidence · combination | 29.3% (n=3246)e,d,f,b NCT02941926 · Phase 3 · combination 3 other source trials41.5% (n=188)400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 45.3% (n=188)600 mg NCT03822468 · Phase 2 · registry result, not featured evidence 16.7% (n=12) NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination |
| ORR event count · % of participants No placebo or comparator arm | 33.3% (n=54)*d,b NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted 8 other source trials0% (n=3) @ 24wk*100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=3) @ 24wk*150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 6.7% (n=15) @ 24wk*150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted 10% (n=10) @ 24wk*300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted 0% (n=16) @ 24wk*50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=6) @ 24wk*75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 0% (n=3) @ 24wk*75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted 4% (n=75) @ 24wk*50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 3 Participants as posted | 50% (n=2)*d,b NCT03477396 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted |
| Overall Survival time to event · months | 53.9 vs 51.2 placebo monthsg,a,b NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose53.8 vs 49.8 placebo months NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 | NA vs 40 placebo monthsa,b NCT02422615 · Phase 3 · combination 5 other source trialsNA vs 40.9 placebo months NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 63.9 vs 51.4 placebo months NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 NA vs 55.5 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence 69.2 vs 55.5 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence NA vs NA Combination Chemotherapy months600 mg NCT03839823 · Phase 2 · registry result, not featured evidence |
| Overall Survival time to event · months No placebo or comparator arm | 35.61 months*e,d,b NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1084 days as posted 6 other source trials20.73 months100mg NCT02630693 · Phase 2 · registry result, not featured evidence 21.39 months125mg NCT02630693 · Phase 2 · registry result, not featured evidence NA months NCT03530696 · Phase 2 · registry result, not featured evidence 35.1 months NCT03530696 · Phase 2 · registry result, not featured evidence · combination 37.9 months NCT03691493 · Phase 2 · registry result, not featured evidence · combination NA months125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination | NA monthsg,e,d,b NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more dosesNA months NCT03096847 · Phase 3 · registry result, not featured evidence · combination NA months NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| Overall Survival responder rate · % of participants No placebo or comparator arm | 90% (n=10) @ 48wk300 mg QDg,i,d,j NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy show 7 more doses100% (n=3) @ 48wk150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100% (n=15) @ 48wk150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100% (n=3) @ 48wk100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 83.3% (n=6) @ 48wk75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100% (n=3) @ 48wk75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100% (n=16) @ 48wk50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 84.2% (n=75) @ 48wk50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy | 93.3% (n=307) @ 48wkg,i,d,j NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more doses87.5% (n=26) @ 48wk NCT03096847 · Phase 3 · registry result, not featured evidence · combination 86.1% (n=154) @ 48wk NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| PFS time to event · months | 24.8 vs 14.5 placebo monthsa,b NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 9 other source trials9.2 vs 3.8 Fulvestrant months NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 21.5 vs 13.9 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 21.6 vs 16.4 placebo months NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 7.3 vs 9.4 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 7.5 vs 9.4 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 8 vs 10.6 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 26.1 vs 10.2 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 18.1 vs 10.2 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20.2 vs 10.2 Letrozole months NCT00721409 · Phase 2 · registry result, not featured evidence · combination | 20.5 vs 12.8 placebo monthsg,a,b NCT02422615 · Phase 3 · combination show 1 more doseNA vs 10.9 placebo months NCT02422615 · Phase 3 · combination |
| PFS time to event · months No placebo or comparator arm | 29.4 months*e,d,b NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted 8 other source trials9.33 months100mg NCT02630693 · Phase 2 · registry result, not featured evidence 11.3 months125mg NCT02630693 · Phase 2 · registry result, not featured evidence 9.13 months NCT02668666 · Phase 2 · registry result, not featured evidence 8.3 months NCT03530696 · Phase 2 · registry result, not featured evidence 16.9 months NCT03530696 · Phase 2 · registry result, not featured evidence · combination 30.4 months NCT03691493 · Phase 2 · registry result, not featured evidence · combination 6.53 months100mg NCT02384239 · Phase 2 · registry result, not featured evidence 9.4 months125mg NCT02384239 · Phase 2 · registry result, not featured evidence | 21.8 monthsg,e,d,b NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more doses16.5 months NCT03096847 · Phase 3 · registry result, not featured evidence · combination 8.8 months NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| Progressive Disease event count · % of participants No placebo or comparator arm Progressive Disease | 36.4% (n=11)*g,k,h,b NCT03530696 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted show 1 more dose14.3% (n=35)* NCT03530696 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted | 75% (n=12) @ 12wk*k,h,b Progressive disease NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 9 Participants as posted |
| Dropout rate | n/a: no completion milestonel NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 48 more resultsn/a: no completion milestone NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestone NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 69.1%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 34%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 19.5% NCT01864746 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02600923 · Phase 3 · registry result, not featured evidence · combination 0% NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 1.1% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 87.5% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 1.1%125mg NCT02630693 · Phase 2 · registry result, not featured evidence 0%100mg NCT02630693 · Phase 2 · registry result, not featured evidence 0% NCT02668666 · Phase 2 · registry result, not featured evidence 1.4% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 1.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02536742 · Phase 2 · registry result, not featured evidence 12.5%Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence 2.6%T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination 2.8% NCT03691493 · Phase 2 · registry result, not featured evidence · combination 3.6% NCT04436744 · Phase 2 · registry result, not featured evidence · combination 0%125mg NCT02384239 · Phase 2 · registry result, not featured evidence 0%100mg NCT02384239 · Phase 2 · registry result, not featured evidence 22.1%B: Letrozole Then Letrozole + Palb NCT02296801 · Phase 2 · registry result, not featured evidence · combination 27.5%C: Palbociclib Then Letrozole + Pa NCT02296801 · Phase 2 · registry result, not featured evidence · combination 13.4%D: Letrozole + Palbociclib NCT02296801 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone125 mg NCT01684215 · Phase 2 · registry result, not featured evidence —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT01684215 · Phase 2 · registry result, not featured evidence —Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 100%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 97.6%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination | n/a: no completion milestoneRibociclib + Fulvestrantm NCT02422615 · Phase 3 · combination show 34 more results—Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination 59.9% NCT02941926 · Phase 3 · combination n/a: no completion milestoneRibociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestoneRibociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 68.7%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 76.9%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 87.9%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestonePK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePostmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePremenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestone600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence n/a: no completion milestone400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0% NCT03477396 · Phase 2 · registry result, not featured evidence · combination 68.8%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 3.2% NCT02632045 · Phase 2 · registry result, not featured evidence · combination 50% NCT03078751 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —500 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —400 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —300 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 7.7%Cohort B: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —Cohort C: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 7.2%l NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 48 more results8.9% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 — NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3.9%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 2%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 5.2%Cohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 2%Cohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 5.2% NCT01864746 · Phase 3 · registry result, not featured evidence 2.3% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination — NCT03633331 · Phase 2 · registry result, not featured evidence · combination — NCT04224272 · Phase 2 · registry result, not featured evidence · combination —125mg NCT02630693 · Phase 2 · registry result, not featured evidence —100mg NCT02630693 · Phase 2 · registry result, not featured evidence — NCT02668666 · Phase 2 · registry result, not featured evidence — NCT03644186 · Phase 2 · registry result, not featured evidence · combination — NCT03007979 · Phase 2 · registry result, not featured evidence · combination — NCT02536742 · Phase 2 · registry result, not featured evidence —Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence —T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination — NCT03691493 · Phase 2 · registry result, not featured evidence · combination 0.9% NCT04436744 · Phase 2 · registry result, not featured evidence · combination —125mg NCT02384239 · Phase 2 · registry result, not featured evidence —100mg NCT02384239 · Phase 2 · registry result, not featured evidence —B: Letrozole Then Letrozole + Palb NCT02296801 · Phase 2 · registry result, not featured evidence · combination —C: Palbociclib Then Letrozole + Pa NCT02296801 · Phase 2 · registry result, not featured evidence · combination —D: Letrozole + Palbociclib NCT02296801 · Phase 2 · registry result, not featured evidence · combination 0%125 mg NCT01684215 · Phase 2 · registry result, not featured evidence —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 16.7%100 mg NCT01684215 · Phase 2 · registry result, not featured evidence —Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 0%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 15.5%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination | 10.5%Ribociclib + Fulvestrantm NCT02422615 · Phase 3 · combination show 34 more results—Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination 15.5% NCT02941926 · Phase 3 · combination 4.8%Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 11.4%Ribociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 22.6%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 23.1%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 17.8%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 11.8%PK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence 6.5%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 1.3%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 12.8%600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence 11.2%400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence — NCT03477396 · Phase 2 · registry result, not featured evidence · combination 7.1%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence — NCT02632045 · Phase 2 · registry result, not featured evidence · combination 15.4% NCT03078751 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —500 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —400 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —300 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —Cohort B: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —Cohort C: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 28.2%l NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 48 more results22.6% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 20.2% NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 29.6%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 18%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 22.7%Cohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 14.1%Cohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 10.1% NCT01864746 · Phase 3 · registry result, not featured evidence 24.6% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 38% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 15.7% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 13.5%125mg NCT02630693 · Phase 2 · registry result, not featured evidence 10%100mg NCT02630693 · Phase 2 · registry result, not featured evidence 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 54.2% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 73% NCT02536742 · Phase 2 · registry result, not featured evidence 21.4%Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence 21.1%T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination — NCT03691493 · Phase 2 · registry result, not featured evidence · combination 4.5% NCT04436744 · Phase 2 · registry result, not featured evidence · combination 5.9%125mg NCT02384239 · Phase 2 · registry result, not featured evidence 13.9%100mg NCT02384239 · Phase 2 · registry result, not featured evidence —B: Letrozole Then Letrozole + Palb NCT02296801 · Phase 2 · registry result, not featured evidence · combination —C: Palbociclib Then Letrozole + Pa NCT02296801 · Phase 2 · registry result, not featured evidence · combination —D: Letrozole + Palbociclib NCT02296801 · Phase 2 · registry result, not featured evidence · combination 0%125 mg NCT01684215 · Phase 2 · registry result, not featured evidence 9.5%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 33.3%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 0%100 mg NCT01684215 · Phase 2 · registry result, not featured evidence 30.3%Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 24%Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 16.7%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 26.5%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20%300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 33.3%150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 0%150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 13.3%150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 16.7%100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 33.3%100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 16.7%75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 11.1%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 0%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 12%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 20%25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 40%25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination | —Ribociclib + Fulvestrantm NCT02422615 · Phase 3 · combination show 34 more results37.1%Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination — NCT02941926 · Phase 3 · combination —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 24.2%Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 25%Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 32.3%Ribociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 30.4%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination 27.3%Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 19.2%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 28.7%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination —PK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 29.4%PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence 0%PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 27.3%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 0%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 17.7%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 0%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —600 mg NCT03822468 · Phase 2 · registry result, not featured evidence 19.7%600mg NCT03822468 · Phase 2 · registry result, not featured evidence —400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 20.2%400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0% NCT03477396 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 15.2%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 6.7% NCT02632045 · Phase 2 · registry result, not featured evidence · combination 15.4% NCT03078751 · Phase 2 · registry result, not featured evidence · combination 100%600 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 100%500 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 100%400 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 100%300 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 83.3%Cohort B: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —Cohort C: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | l neutropenia 69.4% (placebo 3.6%) arthralgia 42.1% (placebo 40.1%) fatigue 41.2% (placebo 29.3%) NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 42 more resultsneutropenia 67% fatigue 43.8% nausea 36.5% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutrophil count decreased 66.7% (placebo 11.1%) white blood cell count decreased 64.3% (placebo 9.9%) neutropenia 44.6% (placebo 7%) NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 72.4% fatigue 65.1% nausea 37.5% NCT02679755 · Phase 4 · registry result, not featured evidence · combination neutropenia 57% anaemia 22% alopecia 17% NCT02679755 · Phase 4 · registry result, not featured evidence · combination neutrophil count decreased 62.7% fatigue 55.3% hypertension 34% NCT02028507 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 63.1% fatigue 51% hypertension 36.9% NCT02028507 · Phase 3 · registry result, not featured evidence · combination leukopenia 99.2% (placebo 69.9%) neutropenia 95.7% (placebo 23.4%) anemia 73.9% (placebo 30.3%) NCT01864746 · Phase 3 · registry result, not featured evidence neutropenia 70% leukopenia 34.6% anaemia 33.8% NCT02600923 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 92.4% white blood cell decreased 87% fatigue 84.8% NCT03633331 · Phase 2 · registry result, not featured evidence · combination diarrhoea 92.2% nausea 52.9% stomatitis 41.2% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 125mg fatigue 82% nausea 53.9% back pain 46.1% NCT02630693 · Phase 2 · registry result, not featured evidence 100mg fatigue 85.6% nausea 52.2% insomnia 48.9% NCT02630693 · Phase 2 · registry result, not featured evidence neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence diarrhea 65.3% anemia 48.6% platelet count decreased 38.9% NCT03644186 · Phase 2 · registry result, not featured evidence · combination white blood cell count decreased 96.3% neutrophil count decreased 87% anemia 79.6% NCT03007979 · Phase 2 · registry result, not featured evidence · combination nausea 57.1% aspartate aminotransferase increased 50% fatigue 50% NCT03530696 · Phase 2 · registry result, not featured evidence neutrophil count decreased 84.2% platelet count decreased 76.3% white blood cell count decreased 76.3% NCT03530696 · Phase 2 · registry result, not featured evidence · combination neutropenia 41.1% neutrophil count decreased 23.2% asthenia 22.3% NCT04436744 · Phase 2 · registry result, not featured evidence · combination 125mg neutrophil count decreased 26.5% hypertension 0% NCT02384239 · Phase 2 · registry result, not featured evidence 100mg neutrophil count decreased 13.9% hypertension 5.6% NCT02384239 · Phase 2 · registry result, not featured evidence 125 mg white blood cell count decreased 83.3% diarrhoea 66.7% neutrophil count decreased 66.7% NCT01684215 · Phase 2 · registry result, not featured evidence 125 mg + 2.5 mg neutrophil count decreased 81% stomatitis 76.2% white blood cell count decreased 71.4% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 125 mg + 2.5 mg neutrophil count decreased 100% white blood cell count decreased 100% diarrhoea 66.7% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 100 mg neutrophil count decreased 83.3% white blood cell count decreased 66.7% aspartate aminotransferase increased 33.3% NCT01684215 · Phase 2 · registry result, not featured evidence neutropenia 78.8% leukopenia 48.5% fatigue 42.4% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 72% fatigue 40% leukopenia 40% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 91.7% fatigue 83.3% leukopenia 66.7% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 74.7% leukopenia 43.4% fatigue 41% NCT00721409 · Phase 2 · registry result, not featured evidence · combination 300 mg QD nausea 40% fatigue 30% headache 30% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 150 mg QD neutrophil count decreased 100% anaemia 66.7% fatigue 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 150 mg BID abdominal pain 66.7% ggt increased 66.7% nausea 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 150 mg QD nausea 40% headache 26.7% hypertension 26.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100 mg QD white blood cell count decreased 91.7% neutrophil count decreased 58.3% anaemia 41.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 100 mg QD abdominal pain upper 33.3% arthralgia 33.3% back pain 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 75 mg BID arthralgia 33.3% fall 33.3% fatigue 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 75 mg QD hypophosphataemia 66.7% blood alkaline phosphatase increased 33.3% breast pain 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 50 mg BID alt increased 50% anaemia 50% cough 50% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 50 mg QD neutrophil count decreased 77.8% white blood cell count decreased 77.8% anaemia 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 50 mg QD fatigue 25% ggt increased 18.8% arthralgia 12.5% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 50 mg QD ggt increased 14.7% covid-19 10.7% ast increased 9.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 25 mg BID nausea 60% neutrophil count decreased 60% white blood cell count decreased 60% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 25 mg QD neutrophil count decreased 80% white blood cell count decreased 70% anaemia 50% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination | m neutropenia 57.8% (placebo 2.5%) nausea 46.8% (placebo 31.1%) diarrhoea 34% (placebo 22.4%) NCT02422615 · Phase 3 · combination show 24 more resultsneutropenia 57.9% (placebo 6.5%) arthralgia 38.8% (placebo 36.2%) neutrophil count decreased 35.5% (placebo 1.5%) NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 nausea 75% (placebo 32.1%) anaemia 50% (placebo 7.3%) diarrhoea 50% (placebo 26.7%) NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 65.3% (placebo 5.5%) nausea 54.8% (placebo 32.1%) fatigue 43.4% (placebo 36.1%) NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 50.8% nausea 40.8% fatigue 38.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 48.1% nausea 42.1% fatigue 40.4% NCT03096847 · Phase 3 · registry result, not featured evidence · combination fatigue 57.7% neutropenia 57.7% hot flush 42.3% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 46.5% nausea 43.3% fatigue 37.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 100% (placebo 23.4%) white blood cell count decreased 100% (placebo 33.8%) anaemia 94.1% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence aspartate aminotransferase increased 12.5% (placebo 40.3%) blood alkaline phosphatase increased 6.3% (placebo 27.3%) blood cholesterol increased 6.3% (placebo 16.9%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 85.7% (placebo 23.4%) white blood cell count decreased 80.5% (placebo 33.8%) anaemia 48.1% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 1.4% (placebo 40.3%) aspartate aminotransferase increased 1.4% (placebo 40.3%) blood bilirubin increased 1.4% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 88.6% (placebo 23.4%) white blood cell count decreased 87.3% (placebo 33.8%) anaemia 55.7% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 2.7% (placebo 23.4%) alanine aminotransferase increased 1.4% (placebo 40.3%) aspartate aminotransferase increased 1.4% (placebo 40.3%) NCT03671330 · Phase 2 · registry result, not featured evidence 600mg neutropenia 66.5% leukopenia 27.7% anaemia 26.1% NCT03822468 · Phase 2 · registry result, not featured evidence 400mg neutropenia 53.2% alanine aminotransferase increased 26.1% aspartate aminotransferase increased 21.8% NCT03822468 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 100% alkaline phosphatase increased 100% aspartate aminotransferase increased 100% NCT03477396 · Phase 2 · registry result, not featured evidence · combination 600 mg neutropenia 65.2% anaemia 35.7% leukopenia 25.9% NCT03839823 · Phase 2 · registry result, not featured evidence neutropenia 71.7% (placebo 15.3%) fatigue 33.3% (placebo 32.2%) aspartate aminotransferase increased 25% (placebo 28.8%) NCT02632045 · Phase 2 · registry result, not featured evidence · combination neutropenia 53.8% (placebo 0%) fatigue 46.2% (placebo 4.2%) nausea 46.2% (placebo 25%) NCT03078751 · Phase 2 · registry result, not featured evidence · combination 600 mg neutrophil count decreased 100% platelet count decreased 100% anemia 66.7% NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 500 mg neutrophil count decreased 100% platelet count decreased 100% anemia 66.7% NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 400 mg anemia 100% platelet count decreased 100% white blood cell decreased 100% NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 300 mg anemia 100% platelet count decreased 100% white blood cell decreased 100% NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination anemia 83.3% diarrhea 41.7% nausea 41.7% NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation context differs: eligible sex differs (ALL versus FEMALE).
- bThe assessment timepoint is not available for both results.
- cTrial phases differ: Phase 2 versus Phase 3.
- dPopulation comparability has not been reviewed for both studies.
- eTrial phases differ: Phase 3 versus Phase 2.
- fTreatment context has not been resolved for both arms.
- gThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- hPopulation context differs: registered conditions differ.
- iTrial phases differ: Phase 3 versus Phase 1/2.
- jTreatment context differs: combination versus monotherapy.
- kTrial phases differ: Phase 1/2 versus Phase 2.
- lPopulation comparability has not been reviewed for 46 of these studies.
- mPopulation comparability has not been reviewed for 31 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Palbociclib
show 1 more result
show 1 more result
show 3 more results
+ 65 further endpoints in the CSV export.
Ribociclib
show 4 more results
+ 36 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Palbociclib's landscape · Ribociclib's landscape